Tolecizumab (PCSK9 Inhibitor)

Phase 2Small molecule

DDaping Hospital and the Research Institute of Surgery of the Third Military Medical University

Tolecizumab (PCSK9 Inhibitor) is one of 14 small molecule programs targeting Colon Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colon AdenocarcinomaRecruiting

Colon AdenocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

15 competitors in Colon Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Approved

3 2

Stivarga

Innohep

Adrucil

2 5

Tecentriq

Roche

Phase 3

2 6

Erbitux

IImclone

Phase 3

2 7

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

1 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 9

Camptosar

Pfizer

Phase 1

1 10

Botensilimab

AAgenus Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Colon Adenocarcinoma

NCT07468630

Clinical

Trials by Indication[1]

Colon Adenocarcinoma1 trial

Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma

Recruiting·—·Phase 2·NCT07468630·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tolecizumab (PCSK9 Inhibitor). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tolecizumab (PCSK9 Inhibitor) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tolecizumab (PCSK9 Inhibitor). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daping Hospital and the Research Institute of Surgery of the Third Military Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDaping Hospital and the Research Institute of Surgery of the Third Military Medical University

Tolecizumab (PCSK9 Inhibitor)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Colon Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News